Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 9, 2009, Pages 1066-1074

  Kashihara, Masaki ^a,b   Azuma, Koichi ^c   Kawahara, Akihiko ^d   Basaki, Yuji ^a   Hattori, Satoshi ^b   Yanagawa, Takashi ^b   Terazaki, Yasuhiro ^c   Takamori, Shinzo ^c   Shirouzu, Kazuo ^c   Aizawa, Hisamichi ^c   Nakano, Kenji ^a   Kage, Masayoshi ^d   Kuwano, Michihiko ^a   Ono, Mayumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

HER2; HER3; NSCLC; YB 1

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; PLATINUM DERIVATIVE; SCATTER FACTOR RECEPTOR; Y BOX BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR RECURRENCE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TUMOR MARKERS, BIOLOGICAL;

EID: 69549091683     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ae2828     Document Type: Article

References (30)

1. Matsumoto K, Wolffe AP. Gene regulation by Y-box proteins: coupling control of transcription and translation. Trends Cell Biol 1998;8:318-323. (Pubitemid 28362589)
2. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003;25:691-698. (Pubitemid 36850797)
3. Kuwano M, Oda Y, Izumi H, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004;3:1485-1492. (Pubitemid 39562593)
4. Kamura T, Yahata H, Amada S, et al. Is nuclear expression of Y-box binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999;85:2450-2454. (Pubitemid 29244855)
5. Oda Y, Ohishi Y, Basaki Y, et al. Prognostic implication of the nuclear localization of the Y-box binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci 2007;98:1020-1026. (Pubitemid 46865386)
6. Ladomery M, Sommerville J. A role for Y-box proteins in cell proliferation. Bioessays 1995;17:9-11.
7. Oda Y, Kohashi K, Yamamoto H, et al. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci 2008;99:726-732.
8. Shibahara K, Sugio K, Osaki T, et al. Nuclear expression of the Y-box binding protein as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001;7:3151-3155. (Pubitemid 32963838)
9. Fujii T, Kawahara A, Basaki Y, et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 2008;68:1504-1512. (Pubitemid 351346859)
10. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007;25:1196-1208. (Pubitemid 46640565)
11. Sutherland BW, Kucab J, Wu J, et al. Akt phosphorylates the Y-box binding protein 1 at Ser 102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005;24:4281-4292. (Pubitemid 40961781)
12. Basaki Y, Hosoi F, Oda Y, et al. Akt-dependent nuclear localization of Y-box binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2007;26:2736-2746. (Pubitemid 46663838)
13. Jurchott K, Bergmann S, Stein U, et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and B1 gene expression. J Biol Chem 2003;278:27988-27996. (Pubitemid 36899994)
14. Bergmann S, Royer-Pokara B, Fietze E, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005;65:4078-4087. (Pubitemid 40775644)
15. Lu ZH, Books JT, Ley TJ. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 2005;25:4625-4637.
16. Uchiumi T, Fotovati A, Sasaguri T, et al. YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation. J Biol Chem 2006;281:40440-40449. (Pubitemid 46041847)
17. Berquin IM, Pang B, Dziubinski ML, et al. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005;24:3177-3186. (Pubitemid 40695086)
18. Wu J, Lee C, Yokom D, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006;66:4872-4879.
19. Janz M, Harbeck N, Dettmar P, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 2002;97:278-282. (Pubitemid 34049016)
20. Stratford AL, Habibi G, Astanehe A, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 2007;9:R61. (Pubitemid 350187482)
21. Ohga T, Koike K, Ono M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cis-platin, mitomycin C, and ultraviolet light. Cancer Res 1996;56:4224-4228. (Pubitemid 26305020)
22. Simpson EH. The interpretation of interaction in contingency table. J R Stat Soc B 1951;13:238-241.
23. Rothman KJ, Greenland S. (1998) Modern Epidemiology, 2nd Ed. Philadelphia: Lippincott-Raven, 1998. P. 113.
24. Hirata A, Hosoi F, Miyagawa M, et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 2005;65:4253-4260. (Pubitemid 40775664)
25. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-2899.
26. Schaefer G, Shao L, Totpal K, Akita RW. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 2007;67:1228-1238. (Pubitemid 46270782)
27. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242-7251. (Pubitemid 46095395)
28. Reinmuth N, Meister M, Muley T, et al. Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. Int J Cancer 2006;119:727-734. (Pubitemid 44051433)
29. Engelman JA. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res 2007;13:4637-4640.
30. Cappuzzo F, Toschi L, Domenichini I, et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 2005;93:1334-1340. (Pubitemid 41752859)